Results for this period
Interim period (second quarter)1 January 2026–30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from the drug discovery and development business increased by ¥440.401 million year on year, while the segment loss narrowed by ¥284.610 million. Revenue from the radiopharmaceuticals business increased by ¥242.781 million, whereas segment profit decreased by ¥193.549 million. Sales and revenue from related products remained firm against a backdrop of greater use of PET diagnostics and growing demand for amyloid PET testing.
Information on significant events and other matters is included. Although an operating loss has been recorded, the company determined that no material uncertainty exists regarding the going-concern assumption, owing to the refinancing of the syndicated loan agreement and sufficient liquidity on hand.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | 9,226 Millions of yen (YoY +8.0%) |
| Operating profit | -2,534 Millions of yen |
| Ordinary income | -2,659 Millions of yen |
| Profit attributable to owners of the parent | -1,999 Millions of yen |
| Net income per share | −¥15.51 |
| Equity ratio | End of the current fiscal period 67.2 / End of previous period 66.9 |
| Total assets | 72,225 Millions of yen |
| Net assets | 48,555 Millions of yen |
| Cash flows from operating activities | ¥-1,820,465 thousand |
| Cash flows from investing activities | ¥-613,871 thousand |
| Cash flows from financing activities | ¥-2,709,586 thousand |
| Cash and cash equivalents at end of period | ¥23,602,821 thousand |
| Full-year earnings forecast | Net Sales 32,000 Millions of yen (YoY +72.8%) / Operating profit 4,600 Millions of yen / Ordinary income 4,300 Millions of yen / Net income 3,000 Millions of yen |
| Annual Dividend Forecast | ¥0.00 → ¥0.00（0.0） |
| Segment revenue | Drug discovery and development business ¥1,201,136 thousand / Radiopharmaceutical Business ¥8,025,834 thousand |
| Segment profit | Drug discovery and development business ¥-2,731,999 thousand / Radiopharmaceutical Business ¥242,216 thousand |
| Depreciation and amortization | 998 Millions of yen |
| Impairment loss | None recorded (the reconciliation table shows "-" for impairment losses on property, plant and equipment, intangible assets and goodwill) |
| Disclosure regarding the going concern assumption | Information on significant events and other matters is included. Although an operating loss has been recorded, the company determined that no material uncertainty exists regarding the going-concern assumption, owing to the refinancing of the syndicated loan agreement and sufficient liquidity on hand. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | Newly consolidated: 0 companies; excluded: 0 companies (no material change in the scope of consolidation) |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 130,010,400 Shares |
| Treasury Shares at Period-End | 1,442,676 Shares |
| Factors Behind Changes in Business Performance | Revenue from the drug discovery and development business increased by ¥440.401 million year on year, while the segment loss narrowed by ¥284.610 million. Revenue from the radiopharmaceuticals business increased by ¥242.781 million, whereas segment profit decreased by ¥193.549 million. Sales and revenue from related products remained firm against a backdrop of greater use of PET diagnostics and growing demand for amyloid PET testing. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the drug discovery and development business increased by ¥440.401 million year on year, while revenue from the radiopharmaceuticals business increased by ¥242.781 million. The company explained that sales and revenue from related products remained firm against a backdrop of greater use of PET diagnostics and growing demand for amyloid PET testing.